Cellosaurus logo
expasy logo

Cellosaurus COLO 357 (CVCL_0221)

[Text version]
Cell line name COLO 357
Synonyms COLO-357; Colo-357; Colo 357; COLO #357; COLO357; Colo357; Colorado 357
Accession CVCL_0221
Resource Identification Initiative To cite this cell line use: COLO 357 (RRID:CVCL_0221)
Comments Population: African American.
Doubling time: 21 hours (PubMed=6989766).
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Celiac axis lymph node; UBERON=UBERON_0002508.
Sequence variations
Disease Pancreatic adenosquamous carcinoma (NCIt: C5721)
Squamous cell carcinoma of pancreas (ORDO: Orphanet_424039)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RL60 (COLO 357-TRS4)CVCL_8196 (COLO 357/FG)CVCL_IP74 (COLO 357/SG)
Sex of cell Female
Age at sampling 77Y
Category Cancer cell line
STR profile Source(s): Genomics_Center_BCF_Technion

Markers:
AmelogeninX
CSF1PO11
D1S165615
D2S44111
D2S133821,24
D3S135815
D5S81811
D7S8208,10
D8S117914
D10S124813,15
D12S39118
D13S31711
D16S5399,12
D18S5113
D19S43311,13
D21S1129,32.2
D22S104511
FGA25
Penta D5,9
Penta E8,9
TH017
TPOX8
vWA18

Run an STR similarity search on this cell line
Web pages https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/Colo%20357.html
Publications

PubMed=6989766; DOI=10.1002/ijc.2910250507
Morgan R.T., Woods L.K., Moore G.E., Quinn L.A., McGavran L., Gordon S.G.
Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma.
Int. J. Cancer 25:591-598(1980)

PubMed=6277475
Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E., Moseley J.M., Martin T.J.
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.
Cancer Res. 42:1116-1119(1982)

PubMed=6435863
Chang B.K., Black O. Jr., Gutman R.
Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II).
Cancer Res. 44:5100-5104(1984)

PubMed=3815343
Kajiji S.M., Davceva B., Quaranta V.
Six monoclonal antibodies to human pancreatic cancer antigens.
Cancer Res. 47:1367-1376(1987)

PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

PubMed=8426738
Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W.
p53 and K-RAS alterations in pancreatic epithelial cell lesions.
Oncogene 8:289-298(1993)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer Res. 66:7920-7928(2006)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

DOI=10.4172/2324-9293.1000104
Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.
Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.
Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

Cross-references
Cell line collections (Providers) ECACC; 94072245 - Discontinued
Cell line databases/resources CLO; CLO_0002548
MCCL; MCC:0000506
CLDB; cl5052
cancercelllines; CVCL_0221
Cell_Model_Passport; SIDM01654
Anatomy/cell type resources BTO; BTO:0003440
Chemistry resources ChEMBL-Cells; CHEMBL3307702
ChEMBL-Targets; CHEMBL614778
PubChem_Cell_line; CVCL_0221
Encyclopedic resources Wikidata; Q54814099
Experimental variables resources EFO; EFO_0002710
Gene expression databases GEO; GSM621898
Polymorphism and mutation databases Cosmic; 685615
Cosmic; 724642
Cosmic; 736272
Cosmic; 808167
Cosmic; 922258
Cosmic; 933529
Cosmic; 949233
Cosmic; 1006371
Cosmic; 1198206
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number30